Affordability
We aim to challenge the dominance of US "Big Pharma" by reducing the burden of high cost vaccines & biologics on the Canadian taxpayer through leveraging domestic manufacturing capabilities.
Produce affordable pharmaceuticals through licensing global innovations and utilizing Canadian biomanufacturing infrastructure.
Since 2024, Asgard Pharmaceuticals is a Canadian venture focused on licensing innovative vaccines and
biologic therapeutics developed abroad, and bringing them to market in Canada. Our mission is to delivery
affordable vaccines and biologics to Canadians by leveraging domestic manufacturing capabilities and AI
systems.
We aim to challenge the dominance of foreign multinationals and "Big Pharma" by reducing the burden of high
cost vaccines on the taxpayer. The COVID-19 pandemic highlighted the decades-long decline in Canada's
domestic biopharmaceutical capacity, creating a critical need to rebuild our national self-sufficiency in
this vital sector. By reinvesting in Canada's national healthcare sovereignty, our vision is to become
Canada's first agile, cost-efficient bridge for licensing, developing, and commercializing foreign
intellectual property innovations.
We aim to challenge the dominance of US "Big Pharma" by reducing the burden of high cost vaccines & biologics on the Canadian taxpayer through leveraging domestic manufacturing capabilities.
Become Canada's first agile, cost-efficient bridge for licensing, developing, and commercializing innovative foreign intellectual property in large molecule pharmaceuticals.
Canada was once a leader in public vaccine manufacturing
Essential medicines in Canada are expensive, delayed, and dangerously dependent on foreign control.
Even with public and private coverage, patients still pay high out-of-pocket costs—while taxpayers foot inflated bills driven by pharma pricing power.
Canada relies on foreign pharma giants, with little control over supply, pricing, or production.
Pandemics and geopolitics have exposed our inability to produce critical medicines when it matters most.
Cutting-edge therapies abroad are delayed or unavailable in Canada due to lack of domestic licensing and trial pathways.
License late-phase global innovations and invest in Canadian-led development and commercialization, building a resilient domestic pipeline.
Facilities like the Biologics Manufacturing Centre (BMC) represent untapped national capacity.
Avoid traditional R&D overhead and global distribution markups to offer affordable, locally made biologics for both patients and healthcare systems.
Minimizing cost allows minimizing excessive markups to patients while still offering high-quality medicines.
If drug development is supported by taxpayer dollars, then the public deserves access to its rewards—not just private shareholders.
We believe that public funding should yield public returns.
We believe in a resilient, self-sufficient Canadian pharmaceutical system, free of foreign interference, ready for pandemics and supply chain shocks.